Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

Jason A. Dubovsky, Ryan Flynn, Jing Du, Bonnie K. Harrington, Yiming Zhong, Benjamin Kaffenberger, Carrie Yang, William H. Towns, Amy Lehman, Amy J. Johnson, Natarajan Muthusamy, Steven M. Devine, Samantha Jaglowski, Jonathan S. Serody, William J. Murphy, David H Munn, Leo Luznik, Geoffrey R. Hill, Henry K. Wong, Kelli K.P. MacDonaldIvan Maillard, John Koreth, Laurence Elias, Corey Cutler, Robert J. Soiffer, Joseph H. Antin, Jerome Ritz, Angela Panoskaltsis-Mortari, John C. Byrd, Bruce R. Blazar

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and current therapies do not completely prevent and/or treat cGVHD. CD+ T cells and B cells mediate cGVHD; therefore, targeting these populations may inhibit cGVHD pathogenesis. Ibrutinib is an FDA-approved irreversible inhibitor of Bruton's tyrosine kinase (BTK) and IL- inducible T cell kinase (ITK) that targets Th cells and B cells and produces durable remissions in B cell malignancies with minimal toxicity. Here, we evaluated whether ibrutinib could reverse established cGVHD in complementary murine models, a model interrogating T cell-driven sclerodermatous cGVHD and an alloantibody-driven multiorgan system cGVHD model that induces bronchiolar obliterans (BO). In the T cell-mediated sclerodermatous cGVHD model, ibrutinib treatment delayed progression, improved survival, and ameliorated clinical and pathological manifestations. In the alloantibody-driven cGVHD model, ibrutinib treatment restored pulmonary function and reduced germinal center reactions and tissue immunoglobulin deposition. Animals lacking BTK and ITK did not develop cGVHD, indicating that these molecules are critical to cGVHD development. Furthermore, ibrutinib treatment reduced activation of T and B cells from patients with active cGVHD. Our data demonstrate that B cells and T cells drive cGVHD and suggest that ibrutinib has potential as a therapeutic agent, warranting consideration for cGVHD clinical trials.

Original languageEnglish (US)
Pages (from-to)4867-4876
Number of pages10
JournalJournal of Clinical Investigation
Volume124
Issue number11
DOIs
StatePublished - Nov 3 2014

Fingerprint

Graft vs Host Disease
B-Lymphocytes
Therapeutics
T-Lymphocytes
Isoantibodies
PCI 32765
Germinal Center
Hematopoietic Stem Cell Transplantation
Immunoglobulins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dubovsky, J. A., Flynn, R., Du, J., Harrington, B. K., Zhong, Y., Kaffenberger, B., ... Blazar, B. R. (2014). Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. Journal of Clinical Investigation, 124(11), 4867-4876. https://doi.org/10.1172/JCI75328

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. / Dubovsky, Jason A.; Flynn, Ryan; Du, Jing; Harrington, Bonnie K.; Zhong, Yiming; Kaffenberger, Benjamin; Yang, Carrie; Towns, William H.; Lehman, Amy; Johnson, Amy J.; Muthusamy, Natarajan; Devine, Steven M.; Jaglowski, Samantha; Serody, Jonathan S.; Murphy, William J.; Munn, David H; Luznik, Leo; Hill, Geoffrey R.; Wong, Henry K.; MacDonald, Kelli K.P.; Maillard, Ivan; Koreth, John; Elias, Laurence; Cutler, Corey; Soiffer, Robert J.; Antin, Joseph H.; Ritz, Jerome; Panoskaltsis-Mortari, Angela; Byrd, John C.; Blazar, Bruce R.

In: Journal of Clinical Investigation, Vol. 124, No. 11, 03.11.2014, p. 4867-4876.

Research output: Contribution to journalArticle

Dubovsky, JA, Flynn, R, Du, J, Harrington, BK, Zhong, Y, Kaffenberger, B, Yang, C, Towns, WH, Lehman, A, Johnson, AJ, Muthusamy, N, Devine, SM, Jaglowski, S, Serody, JS, Murphy, WJ, Munn, DH, Luznik, L, Hill, GR, Wong, HK, MacDonald, KKP, Maillard, I, Koreth, J, Elias, L, Cutler, C, Soiffer, RJ, Antin, JH, Ritz, J, Panoskaltsis-Mortari, A, Byrd, JC & Blazar, BR 2014, 'Ibrutinib treatment ameliorates murine chronic graft-versus-host disease', Journal of Clinical Investigation, vol. 124, no. 11, pp. 4867-4876. https://doi.org/10.1172/JCI75328
Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. Journal of Clinical Investigation. 2014 Nov 3;124(11):4867-4876. https://doi.org/10.1172/JCI75328
Dubovsky, Jason A. ; Flynn, Ryan ; Du, Jing ; Harrington, Bonnie K. ; Zhong, Yiming ; Kaffenberger, Benjamin ; Yang, Carrie ; Towns, William H. ; Lehman, Amy ; Johnson, Amy J. ; Muthusamy, Natarajan ; Devine, Steven M. ; Jaglowski, Samantha ; Serody, Jonathan S. ; Murphy, William J. ; Munn, David H ; Luznik, Leo ; Hill, Geoffrey R. ; Wong, Henry K. ; MacDonald, Kelli K.P. ; Maillard, Ivan ; Koreth, John ; Elias, Laurence ; Cutler, Corey ; Soiffer, Robert J. ; Antin, Joseph H. ; Ritz, Jerome ; Panoskaltsis-Mortari, Angela ; Byrd, John C. ; Blazar, Bruce R. / Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 11. pp. 4867-4876.
@article{a9c77b2f10674b3c9cae92e690147a8e,
title = "Ibrutinib treatment ameliorates murine chronic graft-versus-host disease",
abstract = "Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and current therapies do not completely prevent and/or treat cGVHD. CD+ T cells and B cells mediate cGVHD; therefore, targeting these populations may inhibit cGVHD pathogenesis. Ibrutinib is an FDA-approved irreversible inhibitor of Bruton's tyrosine kinase (BTK) and IL- inducible T cell kinase (ITK) that targets Th cells and B cells and produces durable remissions in B cell malignancies with minimal toxicity. Here, we evaluated whether ibrutinib could reverse established cGVHD in complementary murine models, a model interrogating T cell-driven sclerodermatous cGVHD and an alloantibody-driven multiorgan system cGVHD model that induces bronchiolar obliterans (BO). In the T cell-mediated sclerodermatous cGVHD model, ibrutinib treatment delayed progression, improved survival, and ameliorated clinical and pathological manifestations. In the alloantibody-driven cGVHD model, ibrutinib treatment restored pulmonary function and reduced germinal center reactions and tissue immunoglobulin deposition. Animals lacking BTK and ITK did not develop cGVHD, indicating that these molecules are critical to cGVHD development. Furthermore, ibrutinib treatment reduced activation of T and B cells from patients with active cGVHD. Our data demonstrate that B cells and T cells drive cGVHD and suggest that ibrutinib has potential as a therapeutic agent, warranting consideration for cGVHD clinical trials.",
author = "Dubovsky, {Jason A.} and Ryan Flynn and Jing Du and Harrington, {Bonnie K.} and Yiming Zhong and Benjamin Kaffenberger and Carrie Yang and Towns, {William H.} and Amy Lehman and Johnson, {Amy J.} and Natarajan Muthusamy and Devine, {Steven M.} and Samantha Jaglowski and Serody, {Jonathan S.} and Murphy, {William J.} and Munn, {David H} and Leo Luznik and Hill, {Geoffrey R.} and Wong, {Henry K.} and MacDonald, {Kelli K.P.} and Ivan Maillard and John Koreth and Laurence Elias and Corey Cutler and Soiffer, {Robert J.} and Antin, {Joseph H.} and Jerome Ritz and Angela Panoskaltsis-Mortari and Byrd, {John C.} and Blazar, {Bruce R.}",
year = "2014",
month = "11",
day = "3",
doi = "10.1172/JCI75328",
language = "English (US)",
volume = "124",
pages = "4867--4876",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "11",

}

TY - JOUR

T1 - Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

AU - Dubovsky, Jason A.

AU - Flynn, Ryan

AU - Du, Jing

AU - Harrington, Bonnie K.

AU - Zhong, Yiming

AU - Kaffenberger, Benjamin

AU - Yang, Carrie

AU - Towns, William H.

AU - Lehman, Amy

AU - Johnson, Amy J.

AU - Muthusamy, Natarajan

AU - Devine, Steven M.

AU - Jaglowski, Samantha

AU - Serody, Jonathan S.

AU - Murphy, William J.

AU - Munn, David H

AU - Luznik, Leo

AU - Hill, Geoffrey R.

AU - Wong, Henry K.

AU - MacDonald, Kelli K.P.

AU - Maillard, Ivan

AU - Koreth, John

AU - Elias, Laurence

AU - Cutler, Corey

AU - Soiffer, Robert J.

AU - Antin, Joseph H.

AU - Ritz, Jerome

AU - Panoskaltsis-Mortari, Angela

AU - Byrd, John C.

AU - Blazar, Bruce R.

PY - 2014/11/3

Y1 - 2014/11/3

N2 - Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and current therapies do not completely prevent and/or treat cGVHD. CD+ T cells and B cells mediate cGVHD; therefore, targeting these populations may inhibit cGVHD pathogenesis. Ibrutinib is an FDA-approved irreversible inhibitor of Bruton's tyrosine kinase (BTK) and IL- inducible T cell kinase (ITK) that targets Th cells and B cells and produces durable remissions in B cell malignancies with minimal toxicity. Here, we evaluated whether ibrutinib could reverse established cGVHD in complementary murine models, a model interrogating T cell-driven sclerodermatous cGVHD and an alloantibody-driven multiorgan system cGVHD model that induces bronchiolar obliterans (BO). In the T cell-mediated sclerodermatous cGVHD model, ibrutinib treatment delayed progression, improved survival, and ameliorated clinical and pathological manifestations. In the alloantibody-driven cGVHD model, ibrutinib treatment restored pulmonary function and reduced germinal center reactions and tissue immunoglobulin deposition. Animals lacking BTK and ITK did not develop cGVHD, indicating that these molecules are critical to cGVHD development. Furthermore, ibrutinib treatment reduced activation of T and B cells from patients with active cGVHD. Our data demonstrate that B cells and T cells drive cGVHD and suggest that ibrutinib has potential as a therapeutic agent, warranting consideration for cGVHD clinical trials.

AB - Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and current therapies do not completely prevent and/or treat cGVHD. CD+ T cells and B cells mediate cGVHD; therefore, targeting these populations may inhibit cGVHD pathogenesis. Ibrutinib is an FDA-approved irreversible inhibitor of Bruton's tyrosine kinase (BTK) and IL- inducible T cell kinase (ITK) that targets Th cells and B cells and produces durable remissions in B cell malignancies with minimal toxicity. Here, we evaluated whether ibrutinib could reverse established cGVHD in complementary murine models, a model interrogating T cell-driven sclerodermatous cGVHD and an alloantibody-driven multiorgan system cGVHD model that induces bronchiolar obliterans (BO). In the T cell-mediated sclerodermatous cGVHD model, ibrutinib treatment delayed progression, improved survival, and ameliorated clinical and pathological manifestations. In the alloantibody-driven cGVHD model, ibrutinib treatment restored pulmonary function and reduced germinal center reactions and tissue immunoglobulin deposition. Animals lacking BTK and ITK did not develop cGVHD, indicating that these molecules are critical to cGVHD development. Furthermore, ibrutinib treatment reduced activation of T and B cells from patients with active cGVHD. Our data demonstrate that B cells and T cells drive cGVHD and suggest that ibrutinib has potential as a therapeutic agent, warranting consideration for cGVHD clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84908656083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908656083&partnerID=8YFLogxK

U2 - 10.1172/JCI75328

DO - 10.1172/JCI75328

M3 - Article

C2 - 25271622

AN - SCOPUS:84908656083

VL - 124

SP - 4867

EP - 4876

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 11

ER -